Applied Therapeutics (NASDAQ:APLT) Downgraded by William Blair to “Market Perform”

William Blair lowered shares of Applied Therapeutics (NASDAQ:APLT) from an outperform rating to a market perform rating in a report issued on Monday, MarketBeat.com reports.

Several other analysts also recently weighed in on APLT. UBS Group reiterated a “neutral” rating and set a $2.00 price target (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Leerink Partners upped their target price on Applied Therapeutics from $11.00 to $14.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Robert W. Baird reduced their price target on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, November 29th. Citigroup dropped their price objective on shares of Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Finally, Royal Bank of Canada reduced their target price on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a report on Friday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.10.

Applied Therapeutics Trading Down 1.5 %

NASDAQ:APLT opened at $0.87 on Monday. The company has a market capitalization of $100.85 million, a P/E ratio of -0.54 and a beta of 1.77. Applied Therapeutics has a 12 month low of $0.78 and a 12 month high of $10.62. The firm has a fifty day simple moving average of $6.47 and a 200-day simple moving average of $6.12.

Institutional Trading of Applied Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. purchased a new position in Applied Therapeutics during the second quarter worth approximately $54,000. Principal Financial Group Inc. acquired a new position in shares of Applied Therapeutics during the 2nd quarter worth approximately $54,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Applied Therapeutics during the 3rd quarter valued at approximately $149,000. SG Americas Securities LLC acquired a new stake in Applied Therapeutics in the 2nd quarter valued at $87,000. Finally, Intech Investment Management LLC purchased a new stake in Applied Therapeutics in the 3rd quarter worth $162,000. 98.31% of the stock is owned by hedge funds and other institutional investors.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.